

About Us

GTC offers advanced genomic profiling of DNA/RNA for both solid and hematologic cancers to communities everywhere. We have a TAT of 7-10 days and a QNS rate of <1%.

Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC's testing is covered by Medicare and most insurances.

Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction. Our RNA profiling can be used to compliment flow cytometry and immunohistochemistry (IHC) testing. GTC's capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn't available.